Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Atezolizumab + D2C7-IT|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Atezolizumab||Tecentriq||RG7446|MPDL3280A||Immune Checkpoint Inhibitor 95 PD-L1/PD-1 antibody 58||Tecentriq (atezolizumab) is a monoclonal antibody against PD-L1 (CD274), preventing activation of its receptor, potentially enhancing T-cell-mediated immune response to neoplasms and inhibiting T-cell inactivation (PMID: 29449897). Tecentriq (atezolizumab) is FDA approved for use in patients with advanced urothelial carcinoma, metastatic non-small cell lung cancer (NSCLC) progressed on platinum-containing therapy, in combination with bevacizumab, paclitaxel, and carboplatin for non-squamous NSCLC with no EGFR or ALK aberrations, in combination with paclitaxel protein-bound for advanced or metastatic triple-negative breast cancer expressing PD-L1, and in combination with carboplatin and etoposide for small cell lung cancer (FDA.gov).|
|D2C7-IT||D2C7-(scdsFv)-PE38KDEL||D2C7-IT is an immunotoxin engineered by linking a fragment of the D2C7 monoclonal antibody recognizing wild-type EGFR and EGFRvIII with Pseudomonas Exotoxin A (PE38KDEL), which targets tumor cells expressing wild-type EGFR and/or EGFRvIII, potentially resulting in decreased tumor growth (PMID: 28286803).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT04160494||Phase I||Atezolizumab + D2C7-IT||D2C7-IT With Atezolizumab for Recurrent Gliomas||Recruiting|